These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32560058)

  • 1. High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor.
    Dellal H; Boulahtouf A; Alaterre E; Cuenant A; Grimaldi M; Bourguet W; Gongora C; Balaguer P; Pourquier P
    Cells; 2020 Jun; 9(6):. PubMed ID: 32560058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-competitive androgen receptor inhibition in vitro and in vivo.
    Jones JO; Bolton EC; Huang Y; Feau C; Guy RK; Yamamoto KR; Hann B; Diamond MI
    Proc Natl Acad Sci U S A; 2009 Apr; 106(17):7233-8. PubMed ID: 19363158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
    Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
    Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
    Wu M; Xie Y; Cui X; Huang C; Zhang R; He Y; Li X; Liu M; Cen S; Zhou J
    Eur J Med Chem; 2019 Mar; 166():232-242. PubMed ID: 30711833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
    Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
    Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
    Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade.
    Rosette C; Agan FJ; Rosette N; Mazzetti A; Moro L; Gerloni M
    Mol Cancer Ther; 2020 Nov; 19(11):2256-2266. PubMed ID: 32847976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and biological characterization of a novel series of androgen receptor modulators.
    Zhou C; Wu G; Feng Y; Li Q; Su H; Mais DE; Zhu Y; Li N; Deng Y; Yang D; Wang MW
    Br J Pharmacol; 2008 May; 154(2):440-50. PubMed ID: 18414397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.
    Johnston PA; Nguyen MM; Dar JA; Ai J; Wang Y; Masoodi KZ; Shun T; Shinde S; Camarco DP; Hua Y; Huryn DM; Wilson GM; Lazo JS; Nelson JB; Wipf P; Wang Z
    Assay Drug Dev Technol; 2016 May; 14(4):226-39. PubMed ID: 27187604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computationally guided discovery of novel non-steroidal AR-GR dual antagonists demonstrating potency against antiandrogen resistance.
    Chai X; Hu XP; Wang XY; Wang HT; Pang JP; Zhou WF; Liao JN; Shan LH; Xu XH; Xu L; Xia HG; Hou TJ; Li D
    Acta Pharmacol Sin; 2023 Jul; 44(7):1500-1518. PubMed ID: 36639570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
    Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
    Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.
    Abbasi A; Movahedpour A; Amiri A; Najaf MS; Mostafavi-Pour Z
    Curr Mol Med; 2021; 21(4):332-346. PubMed ID: 32881669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.
    He Y; Hwang DJ; Ponnusamy S; Thiyagarajan T; Mohler ML; Narayanan R; Miller DD
    J Med Chem; 2020 Nov; 63(21):12642-12665. PubMed ID: 33095584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drivers of AR indifferent anti-androgen resistance in prostate cancer cells.
    Handle F; Prekovic S; Helsen C; Van den Broeck T; Smeets E; Moris L; Eerlings R; Kharraz SE; Urbanucci A; Mills IG; Joniau S; Attard G; Claessens F
    Sci Rep; 2019 Sep; 9(1):13786. PubMed ID: 31551480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin.
    Sharma V; Kumar L; Mohanty SK; Maikhuri JP; Rajender S; Gupta G
    Mol Cell Endocrinol; 2016 Aug; 431():12-23. PubMed ID: 27132804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second generation androgen receptor antagonists and challenges in prostate cancer treatment.
    Chen Y; Zhou Q; Hankey W; Fang X; Yuan F
    Cell Death Dis; 2022 Jul; 13(7):632. PubMed ID: 35864113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor antagonists for prostate cancer therapy.
    Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
    Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.